Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.

ABSTRACT: The epidermal growth factor receptor (EGFR) has been recognized as an important therapeutic target in oncology. It is commonly overexpressed in a variety of solid tumors and is critically involved in cell survival, proliferation, metastasis, and angiogenesis. This multi-dimensional role of EGFR in the progression and aggressiveness of cancer, has evolved from conventional to more targeted therapeutic approaches. With the advent of hybridoma technology and phage display techniques, the first anti-EGFR monoclonal antibodies (mAbs) (Cetuximab and Panitumumab) were developed. Due to major limitations including host immune reactions and poor tumor penetration, these antibodies were modified and used as guiding mechanisms for the specific delivery of readily available chemotherapeutic agents or

SUBMITTER: Biteghe FAN 

PROVIDER: S-EPMC7517958 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature